Drug intelligence / Profile preview

Adipocell

Development stage: Unknown
Lead developer: Anterogen
Modality: Cell Therapies
Administration: Subcutaneous

Overview

**Adipocell** is an autologous cultured adipocyte cell therapy developed by Anterogen for treatment of depressed scars. The product is manufactured from a patient's lipoaspirate by isolating and expanding adipose tissue-derived stem cells and differentiating them into immature adipocytes for local subcutaneous administration. Its therapeutic effect is intended to restore deficient soft-tissue volume in scar depressions; implanted adipocytes may also support tissue repair through local paracrine regenerative signaling. Adipocell was evaluated in the Phase II/III study NCT00992147 for depressed scar treatment.

Brand names: Adipocell
Other names: autologous cultured adipocytes

Beyond the preview

Go deeper on Adipocell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adipocell.

Explore the full profile